Table 4.
Overall survival at 2, 3 and 5 years for clinical and cross-validated categories.
| Category | n | 2-year OS (95%CI) | 3-year OS (95%CI) | 5-year OS (95%CI) | |||
|---|---|---|---|---|---|---|---|
| Clinical | Cross-validated | Clinical | Cross-validated | Clinical | Cross-validated | ||
| A | 296 | 93% (91–96) | 93% (91–96) | 90% (86–93) | 90% (86–83) | 88% (84–92) | 88% (84–92) |
| B | 450 | 85% (82–88) | 84% (81–87) | 77% (73–81) | 76% (73–80) | 68% (64–72) | 66% (62–70) |
| C | 227 | 74% (68–80) | 76% (68–84) | 68% (62–75) | 70% (62–79) | 52% (46–60) | 56% (47–67) |
| D | 125 | 57% (49–66) | 57% (50–66) | 50% (42–59) | 50% (42–58) | 41% (33–51) | 40% (33–49) |
| E | 216 | 39% (32–48) | 36% (29–45) | 30% (24–39) | 28% (22–37) | 28% (21–36) | 25% (19–33) |
Detailed comparison of overall survival (OS) with corresponding 95% confidence interval (CI) in each of the clinical and cross-validated risk categories at 2, 3 and 5 years (n = 1314).